01:41 , Jul 13, 2017 |  BC Extra  |  Preclinical News

IL-11 receptor inhibition tied to osteosarcoma

In a paper published in Proceedings of the National Academy of Sciences , researchers showed that targeting the alpha subunit of the IL-11 receptor (IL-11R) with the bone metastasis-targeting peptidomimetic BMTP-11 reduces metastases and tumor...
08:00 , Dec 24, 2012 |  BioCentury  |  Product Development

Shire homes in

Proof-of-concept data in cancer for Arrowhead Research Corp. 's peptide-based tissue targeting platform were good enough to get Shire plc on board to use the technology for rare diseases. Last week, the companies partnered to...
07:00 , Sep 17, 2012 |  BioCentury  |  Product Development

Excited about cycling

New synthesis and screening technologies and the allure of access to previously undruggable targets are driving an explosion of new company formation and deal-making around macrocycles and constrained peptides. While it remains to be seen...
07:00 , Aug 20, 2012 |  BC Week In Review  |  Company News

Arrowhead, Merck deal

Arrowhead partnered with Merck to evaluate a mAb from Arrowhead's human-derived peptide targeting and discovery program. Arrowhead gained the program through its acquisition of Alvos Therapeutics Inc. in April. Merck declined to provide details, while...
07:00 , Apr 16, 2012 |  BC Week In Review  |  Company News

Alvos, Arrowhead deal

Arrowhead acquired Alvos (formerly Mercator Therapeutics Inc. ) for 315,467 shares of Arrowhead restricted common stock valued at about $2 million, based on Arrowhead's close of $6.35 on April 10, before the deal was announced....
08:00 , Jan 30, 2012 |  BC Week In Review  |  Company News

Cerulean management update

Cerulean Pharma Inc. , Cambridge, Mass.   Business: Drug delivery, Cancer   Hired: Chris Guiffre as SVP and CBO, a newly created position, formerly president and CEO of Alvos Therapeutics Inc.  ...
08:00 , Nov 17, 2011 |  BC Innovations  |  Strategy

MD Anderson's private screening

Less than two years after The University of Texas MD Anderson Cancer Center carved up the IP for its in vivo phage display screening platform, the two biotech licensees have preclinical proof-of-concept data and preliminary...
08:00 , Nov 10, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Using in vivo phage selection to identify ligand-receptor pairs in blood vessels In vivo selection of phage display libraries could help identify previously unknown...
07:00 , Apr 21, 2011 |  BC Innovations  |  Strategy

A conversation with Gregory Verdine

What will drugs look like in the coming decade? This is the question being posed by Gregory Verdine and the next-generation therapeutic modalities team he leads at Third Rock Ventures . One answer, Verdine believes,...
08:00 , Jan 20, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Drug delivery

This week in techniques Approach Summary Licensing status Publication and contact information Drug delivery Transferrin-mimicking peptide for delivery of brain cancer therapeutics or imaging agents A transferrin-mimicking peptide could be useful for delivering therapeutic and...